American Psychiatric Association

Buprenorphine made treatment for addiction to opioids available in a daily pill. Trial results to be presented in Atlanta, GA show an implanted form of the drug could make treatment even more convenient.

Researchers report that a complex multimodal program delivered at a dedicated facility and with a primary therapeutic focus on trauma-focused cognitive behavioral therapy appears to significantly reduce Child Post-Traumatic Stress Disorder Symptom Scale (CPPS) scores over 4 weeks.

Study results indicate that electronic health records (EHRs) appear to inadequately capture mental health diagnoses, office visits, hospitalizations, specialty care, and medications, with this missing clinical information raising concerns about medical errors and research integrity.

A group of researchers has proposed an evaluation framework to assist clinicians in evaluating the utility, safety, and efficacy of smartphone apps for psychiatry.

The findings of a systematic meta-review of 13 literature reviews examining 185 distinct studies indicates that the evidence regarding yoga as an intervention for the effects of trauma and the mental health symptoms and illnesses that frequently accompany trauma is encouraging.

Antony Loebel, MD, Executive Vice President and Chief Medical Officer, Sunovion Pharmaceuticals Inc. provided invaluable insight on the first placebo-controlled trial for patients with Major Depressive Disorder with mixed features.

Henry Nasrallah, MD, Sydney W. Souers Endowed Chair, Professor & Chairman, Department of Neurology & Psychiatry, Saint Louis University School of Medicine introduced his research surrounding Parkinson's Disease Psychosis, often considered a new battle field for many psychiatrists.

Patients with schizoaffective disorder who were treated with paliperidone palmitate (as monotherapy and adjunctive therapy) experienced delayed time to relapse and reduced risk of relapse compared to patients treated with placebo.

Adult patients with binge eating disorder who were treated for 12 weeks with lisdexamfetamine dimesylate reported having 4 fewer binge days per week, and also experienced improvements in weight and triglyceride levels.

Patients in a trial of a first-in-class medication for the treatment of female sexual dysfunction reported improvement in overall sexual function, including an increase in the number of satisfying sexual events, and a concomitant decrease in distress levels associated with sexual dysfunction.

Study results presented at the 2014 annual meeting of the American Psychiatric Association show that a reduced dosage of the antidepressant vilazodone is as effective as the currently approved dosage.

Study results presented at the 2014 APA annual meeting show patients treated with vortioxetine significant improvement in composite cognition scores compared to patients treated with placebo, independent of the drug's effect on their depression symptoms.

Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.

By paralyzing the facial muscles involved in producing frown lines, onabotulinumtoxinA injection seems to alleviate depression, especially among patients who exhibit a high degree of hyperactivity.

Small, "naturalistic" study shows treatment with desvenlafaxine produces high rates of symptom improvement and remission with low rates of adverse events in patients with major depressive disorder.

The opioid overdose epidemic and resulting focus on preventing opioid abuse and diversion could threaten access to effective medications for patients with legitimate medical needs.

Among the numerous posters presented on the last day of the conference, the three highlighted here stood out.

This session focused on the latest two sets of the CANMAT guidelines for bipolar disorder and major depressvive disorder.

New understanding and approaches in schizophrenia are emerging and may lead to useful interventions.

New Non-invasive, Non-systemic Treatment Option Gaining Momentum - NeuroStar TMS Therapy Live Expert Demonstration

Nearly 90 posters were presented during the fourth New Research Session at the APA Annual Meeting, with many focused on ziprasidone.

How does video teleconferencing compare to face-to-face visits in the eyes of parents of psychiatric patients?

Two excellent presentations focusing on the Internet and telepsychiatry made up this session.

The current status and major initiatives of the national EHR movement, considerations in EHR selection, and more were discussed.

This symposium included presentations of NNT and NNH analyses of approved pharmacotherapies for various phases of bipolar disorder

This symposium presented five novel applications of IPSRT.

This symposium focused on presenting the most recent results of key projects conducted to evaluate the effects of early detection/intervention strategies.

During the third New Research session, 73 posters were presented. Here, those that were among the best are highlighted.

How race, ethnicity, and culture affect bipolar disorder; dental care and L-lysine treatment in schizophrenia.

Ten of the latest investigations into schizophrenia and bipolar disorder.